JHEP Reports

Article	Citations
Non-alcoholic fatty liver disease: A patient guideline	131
NAFLD and liver transplantation: Disease burden, current management and future challenges	113
Lipid alterations in chronic liver disease and liver cancer	107
Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet – a randomised controlled trial	100
Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment	93
Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors	93
New targets for NAFLD	92
Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma	84
Artificial intelligence in liver diseases: Improving diagnostics, prognostics and response prediction	80
Organoids to model liver disease	78
ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma	77
Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy	77
Single-cell RNA sequencing of human liver reveals hepatic stellate cell heterogeneity	70
Novel vectors and approaches for gene therapy in liver diseases	61
Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease	59
Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg	59
Gut dysbiosis as a driver in alcohol-induced liver injury	58
NAFLD and MAFLD as emerging causes of HCC: A populational study	56
Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B	56
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area	50
Understanding the cellular interactome of non-alcoholic fatty liver disease	46
Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD	45
Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases	43
The ALBI score: From liver function in patients with HCC to a general measure of liver function	42
Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease	41

Cell of origin in biliary tract cancers and clinical implications	41
Our emerging understanding of the roles of long non-coding RNAs in normal liver function, disease, and malignancy	39
Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation	38
The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes	37
Exposure to perfluoroalkyl substances and risk of hepatocellular carcinoma in a multiethnic cohort	37
Assessing the impact of COVID-19 on liver cancer management (CERO-19)	37
Approach to the patient with acute severe autoimmune hepatitis	37
Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation	37
Real-world experience with obeticholic acid in patients with primary biliary cholangitis	37
De novo synthesis of hepatitis B virus nucleocapsids is dispensable for the maintenance and transcriptional regulation of cccDNA	37
The role of cGAS-STING signalling in liver diseases	36
Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis	36
Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D	35
Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis	35
Bile acids contribute to the development of non-alcoholic steatohepatitis in mice	34
Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD – Reconciling the present with the past	33
Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions	33
Liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension	33
Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS	33
New insights on the role of vascular endothelial growth factor in biliary pathophysiology	33
Quality of life and unmet needs in patients with chronic liver disease: A mixed-method systematic review	32
Physical activity is associated with reduced risk of liver disease in the prospective UK Biobank cohort	32
Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD	32
A human liver chimeric mouse model for non-alcoholic fatty liver disease	31
Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis	30
Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey	30
Transforming growth factor β latency: A mechanism of cytokine storage and signalling regulation in liver homeostasis and disease	30
High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma	29
A dynamic association between myosteatosis and liver stiffness: Results from a prospective interventional study in obese patients	28
Evaluating causality of cellular senescence in non-alcoholic fatty liver disease	28
European ‘NAFLD Preparedness Index’ — Is Europe ready to meet the challenge of fatty liver disease?	27
Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets	27
The neurogliovascular unit in hepatic encephalopathy	27
Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction	27
XBP1-mediated activation of the STING signalling pathway in macrophages contributes to liver fibrosis progression	27
New insights into the pathophysiology and clinical care of rare primary liver cancers	26
NASH-related increases in plasma bile acid levels depend on insulin resistance	26
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2	26
Association between remnant lipoprotein cholesterol levels and non-alcoholic fatty liver disease in adolescents	26
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis	25
Influence of surgical approach and quality of resection on the probability of cure for early-stage HCC occurring in cirrhosis	24
Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study	24
Early transplantation maximizes survival in severe acute-on-chronic liver failure: Results of a Markov decision process model	24
Using cell-free DNA for HCC surveillance and prognosis	24
A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation	24
Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity	24
Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance	24
Embedding assessment of liver fibrosis into routine diabetic review in primary care	23
Novel role of macrophage TXNIP-mediated CYLD–NRF2–OASL1 axis in stress-induced liver inflammation and cell death	23
Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC	23

Treating hepatitis D with bulevirtide – Real-world experience from 114 patients	23
Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication	23
Purinergic signalling in liver diseases: Pathological functions and therapeutic opportunities	23
Low-phospholipid-associated cholelithiasis syndrome: Prevalence, clinical features, and comorbidities	23
Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event	23
Low HDL-cholesterol levels predict hepatocellular carcinoma development in individuals with liver fibrosis	22
Histological and serological features of acute liver injury after SARS-CoV-2 vaccination	22
Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma	22
Hepatic sarcoidosis: Clinical characteristics and outcome	22
Non-invasive biomarkers of Fontan-associated liver disease	22
From congestive hepatopathy to hepatocellular carcinoma, how can we improve patient management?	22
Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease	22
Deep learning model for prediction of hepatocellular carcinoma in patients with HBV-related cirrhosis on antiviral therapy	21
Bile acid-receptor TGR5 deficiency worsens liver injury in alcohol-fed mice by inducing intestinal microbiota dysbiosis	21
Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection	21
Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis	21
Targeted long-read sequencing reveals clonally expanded HBV-associated chromosomal translocations in patients with chronic hepatitis B	21
Macrophage MerTK promotes profibrogenic cross-talk with hepatic stellate cells via soluble mediators	21
Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis	21
Cholangiocyte senescence in primary sclerosing cholangitis is associated with disease severity and prognosis	21
ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis	21
Hepatopulmonary syndrome	21
Association of per- and polyfluoroalkyl substance exposure with fatty liver disease risk in US adults	21
Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis	20
Management of splanchnic vein thrombosis	20
TGR5 controls bile acid composition and gallbladder function to protect the liver from bile acid overload	20
Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials	20
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma	20
Epigenetics of alcohol-related liver diseases	19
Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections	19
Case-finding strategies in non-alcoholic fatty liver disease	19
Hepatic microbiome in healthy lean and obese humans	18
Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates	18
Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis	18
Elevated plasma ICAM1 levels predict 28-day mortality in cirrhotic patients with COVID-19 or bacterial sepsis	18
TAK1 deficiency promotes liver injury and tumorigenesis via ferroptosis and macrophage cGAS-STING signalling	18
Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease	17
Evidence for long-term association of virion-delivered HBV core protein with cccDNA independently of viral protein production	17
Where are the children in national hepatitis C policies? A global review of national strategic plans and guidelines	17
Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis	17
Epidemiology of autosomal-dominant polycystic liver disease in Olmsted county	17
Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis	17
The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care	17
Preoperative TIPS prevents the development of postoperative acute-on-chronic liver failure in patients with high CLIF-C AD score	17
Hepatic miR-192-3p reactivation alleviates steatosis by targeting glucocorticoid receptor	16
Molecular characterization of chronic liver disease dynamics: From liver fibrosis to acute-on-chronic liver failure	16
Inborn and acquired risk factors for severe liver disease in Europeans with type 2 diabetes from the UK Biobank	16
Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice	16
Genetic or pharmacological reduction of cholangiocyte senescence improves inflammation and fibrosis in the Mdr2 mouse	16
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals	16
Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure	16
What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association	16
Ablation of liver Fxr results in an increased colonic mucus barrier in mice	15
ZBTB20 regulates WNT/CTNNB1 signalling pathway by suppressing PPARG during hepatocellular carcinoma tumourigenesis	15
CRISPR-targeted genome editing of human induced pluripotent stem cell-derived hepatocytes for the treatment of Wilson’s disease	15
Cell fate analysis of zone 3 hepatocytes in liver injury and tumorigenesis	15
Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial	15
Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis	15
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma	15
Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD	15
Comparison of radiofrequency ablation and ablative external radiotherapy for the treatment of intrahepatic malignancies: A hybrid meta-analysis	15
Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade	14
Impaired SARS-CoV-2-specific T-cell reactivity in patients with cirrhosis following mRNA COVID-19 vaccination	14
Hepatocyte mARC1 promotes fatty liver disease	14
Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort	14
Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study	14
Hepatitis C prevalences in the psychiatric setting: Cost-effectiveness of scaling-up screening and direct-acting antiviral therapy	14
Portal vein recanalisation alone to treat severe portal hypertension in non-cirrhotic patients with chronic extrahepatic portal vein obstruction	14
Abnormal liver tests in patients with SARS-CoV-2 or influenza – prognostic similarities and temporal disparities	14
HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates	14
Higher subcutaneous adipose tissue radiodensity is associated with increased mortality in patients with cirrhosis	14
Humoral immunity in hepatitis B virus infection: Rehabilitating the B in HBV	14
Use of albumin infusion for cirrhosis-related complications: An international position statement	14
Profiling circulating microRNAs in patients with cirrhosis and acute-on-chronic liver failure	14
Emerging roles of circular RNAs in liver cancer	14
Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B	13
A multicenter analysis of the role of prophylactic transfusion of blood products in patients with cirrhosis and esophageal varices undergoing endoscopic band ligation	13
Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate liver steatosis by promoting fatty acid oxidation and reducing fatty acid synthesis	13
Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness	13
Defatting strategies in the current era of liver steatosis	13

Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection	13
Saturated fatty acid-enriched small extracellular vesicles mediate a crosstalk inducing liver inflammation and hepatocyte insulin resistance	13
A small animal model of chronic hepatitis E infection using immunocompromised rats	13
Hepatic decompensation is accelerated in patients with cirrhosis and alpha-1 antitrypsin Pi∗MZ genotype	12
Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis	12
Non-alcoholic fatty liver disease and diabetes mellitus as growing aetiologies of hepatocellular carcinoma	12
Inflammatory conditions play a role in recurrence of PSC after liver transplantation: An international multicentre study	12
Hyperammonaemia induces mitochondrial dysfunction and neuronal cell death	12
Non-alcoholic fatty liver disease in women – Current knowledge and emerging concepts	12
Cellular origins of regenerating liver and hepatocellular carcinoma	12
Spleen volume-based non-invasive tool for predicting hepatic decompensation in people with compensated cirrhosis (CHESS1701)	11
Prevalence, risk factors and diagnostic accuracy of non-invasive tests for NAFLD in people with type 1 diabetes	11
Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF	11
Role of precipitants in transition of acute decompensation to acute-on-chronic liver failure in patients with HBV-related cirrhosis	11
Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study	11
Enhancing interventions for prevention of mother-to-child- transmission of hepatitis B virus	11
Clinical and genetic determinants of the fatty liver–coagulation balance interplay in individuals with metabolic dysfunction	11
Clinical establishment of a laboratory developed quantitative HDV PCR assay on the cobas6800 high-throughput system	11
Blue-collar work is a risk factor for developing IgG4-related disease of the biliary tract and pancreas	11
International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria	11
Abnormal brain oxygen homeostasis in an animal model of liver disease	11
Mitosis of hepatitis B virus-infected cells in vitro results in uninfected daughter cells	11
Balance between macrophage migration inhibitory factor and sCD74 predicts outcome in patients with acute decompensation of cirrhosis	11
Restoration of the gut microbiota is associated with a decreased risk of hepatic encephalopathy after TIPS	11
Molecular epidemiology and clinical characteristics of hepatitis D virus infection in Canada	11
Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis	11
(13C)-Methacetin breath test provides evidence of subclinical liver dysfunction linked to fat storage but not lifestyle	10
Sarcopenia-related gut microbial changes are associated with the risk of complications in people with cirrhosis	10
Waiting time dictates impact of frailty: A Spanish multicenter prospective study	10
Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters	10
Acetaminophen-induced reduction of NIMA-related kinase 7 expression exacerbates acute liver injury	10
Quantitative magnetic resonance cholangiopancreatography metrics are associated with disease severity and outcomes in people with primary sclerosing cholangitis	10
Increased sinusoidal pressure impairs liver endothelial mechanosensing, uncovering novel biomarkers of portal hypertension	10
Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B	10
Mechanobiology of portal hypertension	10
Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice	9
Control of APOBEC3B induction and cccDNA decay by NF-κB and miR-138-5p	9
Physical activity is inversely associated with hepatic fibro-inflammation: A population-based cohort study using UK Biobank data	9
Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases	9
Characterisation of hepatic lipid signature distributed across the liver zonation using mass spectrometry imaging	9
Zinc finger transcription factor Egf1 promotes non-alcoholic fatty liver disease	9
Vessels that encapsulate tumour clusters vascular pattern in hepatocellular carcinoma	9
Dysregulated biomarkers of innate and adaptive immunity predict infections and disease progression in cirrhosis	9
Sex disparities in waitlisting and liver transplant for acute liver failure	9
Long-term results of mycophenolate mofetil vs. azathioprine use in individuals with autoimmune hepatitis	9
Role of ammonia in NAFLD: An unusual suspect	9
Systemic iron reduction by venesection alters the gut microbiome in patients with haemochromatosis	9
Roles of systemic inflammatory and metabolic responses in the pathophysiology of acute-on-chronic liver failure	9
Excellent outcomes with liver transplantation in hepatopulmonary syndrome across pre-transplant PaO2 spectrum	9
Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis	9
High childhood serum triglyceride concentrations associate with hepatocellular adenoma development in patients with glycogen storage disease type Ia	9
Impact of bacterial infections prior to liver transplantation on post-transplant outcomes in patients with cirrhosis	8
Comprehensive assessment of ECM turnover using serum biomarkers establishes PBC as a high-turnover autoimmune liver disease	8
Development of a prognostic MRCP-score (DiStrict) for individuals with large-duct primary sclerosing cholangitis	8
Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis	8
Health inequalities in the management of chronic hepatitis B virus infection in patients from sub-Saharan Africa in high-income countries	8
Marked difference in liver fat measured by histology vs. magnetic resonance-proton density fat fraction: A meta-analysis	8
A novel therapeutic HBV vaccine candidate induces strong polyfunctional cytotoxic T cell responses in mice	8
Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag	8
SCYL3, as a novel binding partner and regulator of ROCK2, promotes hepatocellular carcinoma progression	8
Metabolic reprogramming of hepatocytes by Schistosoma mansoni eggs	8
C–C motif chemokine CCL11 is a novel regulator and a potential therapeutic target in non-alcoholic fatty liver disease	8
Selective disruption of NRF2-KEAP1 interaction leads to NASH resolution and reduction of liver fibrosis in mice	8
An immunoassay system to investigate epidemiology of Rocahepevirus ratti (rat hepatitis E virus) infection in humans	8
CT-derived liver and spleen volume accurately diagnose clinically significant portal hypertension in patients with hepatocellular carcinoma	8
Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma	8
Vaccination in liver diseases and liver transplantation: Recommendations, implications and opportunities in the post-COVID era	8
R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation	8
Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells	7
Conversion of hepatitis B virus relaxed circular to covalently closed circular DNA is supported in murine cells	7
Role of ductular reaction and ductular–canalicular junctions in identifying severe primary biliary cholangitis	7
PI3Kγ promotes obesity-associated hepatocellular carcinoma by regulating metabolism and inflammation	7
A new mouse model of radiation-induced liver disease reveals mitochondrial dysfunction as an underlying fibrotic stimulus	7
Identification and characterisation of a rare MTTP variant underlying hereditary non-alcoholic fatty liver disease	7
MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis	7
Hospice care utilisation among elderly patients who died with hepatocellular carcinoma in the United States	7
B-cell activating factor and IL-21 levels predict treatment response in autoimmune hepatitis	7
Swelling-induced upregulation of miR-141-3p inhibits hepatocyte proliferation	7
Cardiomyopathy in cirrhosis: From pathophysiology to clinical care	7
Incidence of hepatocellular carcinoma in a community-based Taiwanese population without chronic HBV/HCV infection	7
Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer	7
Hepatic venous pressure gradient in sinusoidal obstruction syndrome: Diagnostic value and link with histological lesions	7
Spatial immunophenotypes predict clinical outcome in intrahepatic cholangiocarcinoma	7
Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study	7
Differential blood transcriptome modules predict response to corticosteroid therapy in alcoholic hepatitis	7
Genomic analysis of lean individuals with NAFLD identifies monogenic disorders in a prospective cohort study	7
Molecular clones of genetically distinct hepatitis B virus genotypes reveal distinct host and drug treatment responses	7
Efferocytosis in liver disease	7
Cirrhosis is associated with lower serological responses to COVID-19 vaccines in patients with chronic liver disease	7
Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency	7
Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease	7
Burden, risk factors, and outcomes of multidrug-resistant bacterial colonisation at multiple sites in patients with cirrhosis	7
Immunopeptidome of hepatocytes isolated from patients with HBV infection and hepatocellular carcinoma	7
Circulating indian hedgehog is a marker of the hepatocyte-TAZ pathway in experimental NASH and is elevated in humans with NASH	6
Environmental exposures are important risk factors for advanced liver fibrosis in African American adults	6